X4 Pharmaceuticals
XFOR
60 hedge funds and large institutions have $139M invested in X4 Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
106% more capital invested
Capital invested by funds: $67.3M → $139M (+$71.3M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
13% more funds holding
Funds holding: 53 → 60 (+7)
0.95% more ownership
Funds ownership: 2.14% → 3.09% (+0.95%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$15.7M |
| 2 |
SCM
Sio Capital Management
New York
|
+$7.05M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$6.97M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$5.03M |
| 5 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$4.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$1.17M |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$460K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$430K |
| 4 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
-$347K |
| 5 |
CAM
ClariVest Asset Management
San Diego,
California
|
-$289K |
XFOR Hedge Fund Activity: Q1 2021 in Review
60 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q1 2021, worth a combined $139M — up 106% from $67.3M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new XFOR positions and 5 closed out — a net gain of 7 holders — while 18 added to existing stakes and 15 trimmed.
The largest buyer was Ikarian Capital, adding an estimated $15.7M. The largest seller was State Street, cutting an estimated $1.17M.
- 60 institutional investors held X4 Pharmaceuticals (XFOR) as of Q1 2021, up from 53 in Q4 2020.
- Funds reported $139M of X4 Pharmaceuticals stock for Q1 2021, up 106% quarter-over-quarter.
- 12 funds opened new X4 Pharmaceuticals positions in Q1 2021 and 5 closed out, a net change of +7 holders.
- The largest X4 Pharmaceuticals buyer in Q1 2021 was Ikarian Capital, an estimated $15.7M added.
- The largest X4 Pharmaceuticals seller in Q1 2021 was State Street, an estimated $1.17M sold.
Based on aggregated 13F filings for Q1 2021.